Edition:
United Kingdom

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.46EUR
15 Dec 2017
Change (% chg)

€-0.01 (-1.67%)
Prev Close
€0.47
Open
€0.47
Day's High
€0.48
Day's Low
€0.46
Volume
7,819,835
Avg. Vol
4,288,811
52-wk High
€0.54
52-wk Low
€0.40

Select another date:

Wed, Dec 13 2017

BRIEF-Molmed: Italian Medicines Agency Sets Price Of Reimbursement For Zalmoxis

* ITALIAN MEDICINES AGENCY SETS GROSS PRICE OF REIMBURSEMENT FOR ZALMOXIS AT EUR 149,000 PER INFUSION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed submits utilization request for third tranche of share capital increase

* SUBMITTED UTILIZATION REQUEST FOR THIRD TRANCHE OF SHARE CAPITAL INCREASE TO BE RESERVED TO SOCIETE GENERALE AS PER SEF AGREEMENT

BRIEF-Molmed completes second tranche of share capital increase reserved to Societe Generale

* SECOND TRANCHE OF SHARE CAPITAL INCREASE RESERVED TO SOCIETE GENERALE PURSUANT TO “SEF - STANDBY EQUITY FACILITY” AGREEMENT COMPLETED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed H1 net loss shrinks to EUR 6.5 million

* REPORTED ON THURSDAY H1 OPERATING REVENUE EUR 9.8 MILLION VERSUS 10.2 MILLION A YEAR AGO

BRIEF-Molmed signs development and production agreement with Cellectis

* SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed signs strategic commercialization and supply agreements with Dompe

* MOLMED AND DOMPE SIGN 15-YEAR LICENSE AND DISTRIBUTION AGREEMENT FOR SUPPLY OF ZALMOXIS IN EUROPE

BRIEF-Molmed and TTY Biopharm enter into exclusive agreement to commercialise Zalmoxis in certain Asian territories

* MOLMED AND TTY BIOPHARM ENTER INTO AN EXCLUSIVE AGREEMENT TO COMMERCIALISE ZALMOXIS® IN CERTAIN ASIAN TERRITORIES

Select another date: